Literature DB >> 31015256

Erythropoiesis-Stimulating Agents and Mortality.

Tilman B Drüeke1, Ziad A Massy2,3.   

Abstract

Keywords:  anemia; chronic renal disease; erythropoietin; mortality risk; outcomes

Mesh：

Substances：

Year:  2019        PMID： 31015256      PMCID： PMC6551780          DOI： 10.1681/ASN.2019030266

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  10 in total

1.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

Authors:  Tilman B Drüeke; Francesco Locatelli; Naomi Clyne; Kai-Uwe Eckardt; Iain C Macdougall; Dimitrios Tsakiris; Hans-Ulrich Burger; Armin Scherhag
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

2.  Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Authors:  Finnian R Mc Causland; Brian Claggett; Emmanuel A Burdmann; Glenn M Chertow; Mark E Cooper; Kai-Uwe Eckardt; Peter Ivanovich; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert D Toto; Marc A Pfeffer
Journal:  Am J Kidney Dis       Date:  2018-12-19       Impact factor: 8.860

Review 3.  Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.

Authors:  Emilee R Wilhelm-Leen; Wolfgang C Winkelmayer
Journal:  Am J Kidney Dis       Date:  2015-01-28       Impact factor: 8.860

4.  Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.

Authors:  Wolfgang C Winkelmayer; Tara I Chang; Aya A Mitani; Emilee R Wilhelm-Leen; Victoria Ding; Glenn M Chertow; M Alan Brookhart; Benjamin A Goldstein
Journal:  Am J Kidney Dis       Date:  2015-05-02       Impact factor: 8.860

Review 5.  Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.

Authors:  Valeria M Saglimbene; Suetonia C Palmer; Marinella Ruospo; Patrizia Natale; Jonathan C Craig; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2017-08-07

6.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

7.  Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.

Authors:  Yusuke Sakaguchi; Takayuki Hamano; Atsushi Wada; Ikuto Masakane
Journal:  J Am Soc Nephrol       Date:  2019-04-23       Impact factor: 10.121

8.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

Authors:  A Besarab; W K Bolton; J K Browne; J C Egrie; A R Nissenson; D M Okamoto; S J Schwab; D A Goodkin
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

9.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

Review 10.  Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Authors:  Suetonia C Palmer; Valeria Saglimbene; Dimitris Mavridis; Georgia Salanti; Jonathan C Craig; Marcello Tonelli; Natasha Wiebe; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2014-12-08
  10 in total
  4 in total

1.  Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail.

Authors:  Nan Chen; Changying Xing; Jianying Niu; Bicheng Liu; Junzhou Fu; Jiuyang Zhao; Zhaohui Ni; Mei Wang; Wenhu Liu; Jinghong Zhao; Ling Zhong; Xiongfei Wu; Wenge Li; Yuqing Chen; Wei Shi; Jianghua Chen; Aiping Yin; Ping Fu; Rong Wang; Gengru Jiang; Fanfan Hou; Guohua Ding; Jing Chen; Gang Xu; Yuichiro Kondo; Yuliang Su; Changlin Mei
Journal:  Chronic Dis Transl Med       Date:  2022-03-29

2.  Investigation of the Relationship between Lean Muscle Mass and Erythropoietin Resistance in Maintenance Haemodialysis Patients: A Cross-Sectional Study.

Authors:  Wen-Fang Chiang; Po-Jen Hsiao; Kun-Lin Wu; Hung-Ming Chen; Chi-Ming Chu; Jenq-Shyong Chan
Journal:  Int J Environ Res Public Health       Date:  2022-05-07       Impact factor: 4.614

3.  Dynamics of Erythroferrone Response to Erythropoietin in Rats.

Authors:  Peng Xu; Raymond S M Wong; Wojciech Krzyzanski; Xiaoyu Yan
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

4.  Optimizing detection of erythropoietin receptor agonists from dried blood spots for anti-doping application.

Authors:  Carmel E Heiland; Magnus Ericsson; Anton Pohanka; Lena Ekström; Alexandre Marchand
Journal:  Drug Test Anal       Date:  2022-03-30       Impact factor: 3.234
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.